163 related articles for article (PubMed ID: 34898584)
1. Current Attitudes toward Unfunded Cancer Therapies among Canadian Medical Oncologists.
Wong SK; Gondara L; Gill S
Curr Oncol; 2021 Nov; 28(6):4748-4755. PubMed ID: 34898584
[TBL] [Abstract][Full Text] [Related]
2. Recommending Unfunded Innovative Cancer Therapies: Ethical vs. Clinical Perspectives among Oncologists on a Public Healthcare System-A Mixed-Methods Study.
Bashkin O; Dopelt K; Asna N; Davidovitch N
Curr Oncol; 2021 Aug; 28(4):2902-2913. PubMed ID: 34436020
[TBL] [Abstract][Full Text] [Related]
3. Continental Divide? The attitudes of US and Canadian oncologists on the costs, cost-effectiveness, and health policies associated with new cancer drugs.
Berry SR; Bell CM; Ubel PA; Evans WK; Nadler E; Strevel EL; Neumann PJ
J Clin Oncol; 2010 Sep; 28(27):4149-53. PubMed ID: 20697077
[TBL] [Abstract][Full Text] [Related]
4. Variation and consternation: access to unfunded cancer drugs in Canada.
Berry SR; Evans WK; Strevel EL; Bell CM
J Oncol Pract; 2012 Jan; 8(1):35-9. PubMed ID: 22548009
[TBL] [Abstract][Full Text] [Related]
5. Perceptions and attitudes of medical oncologists regarding fertility preservation and pregnancy in high-risk cancer patients: A survey among Canadian medical oncologists.
Alshamsan B; Kushnir I; Al-Saadi S; Srikanthan A
Cancer Med; 2023 Jan; 12(2):1912-1921. PubMed ID: 35833372
[TBL] [Abstract][Full Text] [Related]
6. Discussing and prescribing expensive unfunded anticancer drugs in Australia.
Karikios DJ; Mileshkin L; Martin A; Ferraro D; Stockler MR
ESMO Open; 2017; 2(2):e000170. PubMed ID: 28761744
[TBL] [Abstract][Full Text] [Related]
7. Oncologists' Perceptions of Drug Affordability Using NCCN Evidence Blocks: Results from a National Survey.
Shah-Manek B; Wong W; Ravelo A; DiBonaventura M
J Manag Care Spec Pharm; 2018 Jun; 24(6):565-571. PubMed ID: 29451078
[TBL] [Abstract][Full Text] [Related]
8. Medical oncologists' views on communicating with patients about chemotherapy costs: a pilot survey.
Schrag D; Hanger M
J Clin Oncol; 2007 Jan; 25(2):233-7. PubMed ID: 17210946
[TBL] [Abstract][Full Text] [Related]
9. Overcoming obstacles in accessing unfunded oral chemotherapy: physician experience and challenges.
Han D; Trinkaus M; Hogeveen S; Mamdani M; Berry SR; Jang RW; Hoch JS; Simmons C
J Oncol Pract; 2013 Jul; 9(4):188-93. PubMed ID: 23942919
[TBL] [Abstract][Full Text] [Related]
10. The effect of priority setting decisions for new cancer drugs on medical oncologists' practice in Ontario: a qualitative study.
Berry SR; Hubay S; Soibelman H; Martin DK
BMC Health Serv Res; 2007 Nov; 7():193. PubMed ID: 18042302
[TBL] [Abstract][Full Text] [Related]
11. Canadian oncologists and clinical practice guidelines: a national survey of attitudes and reported use. Provincial Lung Disease Site Group of Cancer Care Ontario.
Graham ID; Evans WK; Logan D; O'Connor A; Palda V; McAuley L; Brouwers M; Harrison MB
Oncology; 2000 Nov; 59(4):283-90. PubMed ID: 11096339
[TBL] [Abstract][Full Text] [Related]
12. Attitude of Iranian Medical Oncologists Toward Economic Aspects, and Policy-making in Relation to New Cancer Drugs.
Daroudi R; Mirzania M; Zendehdel K
Int J Health Policy Manag; 2015 Oct; 5(2):99-105. PubMed ID: 26927395
[TBL] [Abstract][Full Text] [Related]
13. Less than ideal: how oncologists practice with limited drug access.
Chan KK; Wong B; Siu LL; Straus SE; Chang J; Berry SR
J Oncol Pract; 2012 May; 8(3):190-5. PubMed ID: 22942815
[TBL] [Abstract][Full Text] [Related]
14. Oncologists' opinions towards recommending exercise to patients with cancer: a Canadian national survey.
Jones LW; Courneya KS; Peddle C; Mackey JR
Support Care Cancer; 2005 Nov; 13(11):929-37. PubMed ID: 15809835
[TBL] [Abstract][Full Text] [Related]
15. Perceptions of Oncologists, Healthcare Policy Makers, Patients and the General Population on the Value of Pharmaceutical Treatments in Oncology.
Sacristán JA; Lizan L; Comellas M; Garrido P; Avendaño C; Cruz-Hernández JJ; Espinosa J; Dilla T
Adv Ther; 2016 Nov; 33(11):2059-2068. PubMed ID: 27718158
[TBL] [Abstract][Full Text] [Related]
16. Self-reported practices and attitudes of US oncologists regarding off-protocol therapy.
Peppercorn J; Burstein H; Miller FG; Winer E; Joffe S
J Clin Oncol; 2008 Dec; 26(36):5994-6000. PubMed ID: 19029413
[TBL] [Abstract][Full Text] [Related]
17. Impact of COVID-19 on Canadian medical oncologists and cancer care: Canadian Association of Medical Oncologists survey report.
Gill S; Hao D; Hirte H; Campbell A; Colwell B
Curr Oncol; 2020 Apr; 27(2):71-74. PubMed ID: 32489248
[TBL] [Abstract][Full Text] [Related]
18. American oncologists' views of internet use by cancer patients: a mail survey of American Society of Clinical Oncology members.
Helft PR; Hlubocky F; Daugherty CK
J Clin Oncol; 2003 Mar; 21(5):942-7. PubMed ID: 12610198
[TBL] [Abstract][Full Text] [Related]
19. Attitudes towards open-label versus placebo-control designs in oncology randomized trials: A survey of medical oncologists.
Kushnir I; Clemons M; Fergusson D; Bossé D; Reaume MN
J Eval Clin Pract; 2022 Jun; 28(3):495-499. PubMed ID: 35191169
[TBL] [Abstract][Full Text] [Related]
20. Knowledge and practices of medical oncologists concerning nutrition therapy: A survey study.
Kirbiyik F; Ozkan E
Clin Nutr ESPEN; 2018 Oct; 27():32-37. PubMed ID: 30144890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
